<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE collection SYSTEM "BioC.dtd">
<collection><source>PMC</source><date>20210723</date><key>pmc.key</key><document><id>8267118</id><infon key="license">CC BY</infon><passage><infon key="alt-title">THOMAS et al.</infon><infon key="article-id_doi">10.1002/cam4.3974</infon><infon key="article-id_pmc">8267118</infon><infon key="article-id_pmid">34102000</infon><infon key="article-id_publisher-id">CAM43974</infon><infon key="fpage">4564</infon><infon key="issue">13</infon><infon key="kwd">crowdfunding fundraising GoFundMe insurance kidney neoplasm</infon><infon key="license">This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</infon><infon key="lpage">4574</infon><infon key="name_0">surname:Thomas;given-names:Hannah S.</infon><infon key="name_1">surname:Lee;given-names:Austin W.</infon><infon key="name_10">surname:Breyer;given-names:Benjamin N.</infon><infon key="name_2">surname:Nabavizadeh;given-names:Behnam</infon><infon key="name_3">surname:Namiri;given-names:Nikan K.</infon><infon key="name_4">surname:Hakam;given-names:Nizar</infon><infon key="name_5">surname:Martin‐Tuite;given-names:Patrick</infon><infon key="name_6">surname:Rios;given-names:Natalie</infon><infon key="name_7">surname:Enriquez;given-names:Anthony</infon><infon key="name_8">surname:Mmonu;given-names:Nnenaya A.</infon><infon key="name_9">surname:Cohen;given-names:Andrew J.</infon><infon key="section_type">TITLE</infon><infon key="type">front</infon><infon key="volume">10</infon><infon key="year">2021</infon><offset>0</offset><text>Characterizing online crowdfunding campaigns for patients with kidney cancer</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>77</offset><text>Abstract</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>86</offset><text>Background</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>97</offset><text>Cancer patients incur high care costs; however, there is a paucity of literature characterizing unmet financial obligations for patients with urologic cancers. Kidney cancer patients are particularly burdened by costs associated with novel systemic treatments. This study aimed to ascertain the characteristics of GoFundMe® crowdfunding campaigns for patients with kidney cancer, in order to better understand the financial needs of this population.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>548</offset><text>Methods</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>556</offset><text>We performed a cross‐sectional, quantitative, and qualitative analysis of all kidney cancer GoFundMe® campaigns since 2010. Fundraising metrics such as goal funds and amount raised, were extracted. Eight independent investigators collected patient, disease and campaign‐level variables from campaign stories (κ = 0.72). In addition, we performed a content analysis of campaign narratives spotlighting the primary appeal of the patient's life story.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1013</offset><text>Results</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1021</offset><text>A total of 486 GoFundMe® kidney cancer campaigns were reviewed. The median goal funds were 10,000USD [IQR = 5000, 20,000] and the median amount raised was 1450USD [IQR = 578, 4050]. Most campaigns were for adult males (53%) and 62% of adults had children. A minority were for pediatric patients (17%). Thirty‐seven percent of adult patients were primary wage earners and 43% reported losing their job or substantially reducing hours due to illness. Twenty‐nine percent reported no insurance or insufficient coverage. Campaigns most frequently sought funds for medical bills (60%), nonmedical bills (27%), and medical travel (23%). Qualitative campaign narratives mostly emphasized patients’ hardship (46.3%) or high moral character (35.2%). Only 8% of campaigns achieved their target funds.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1823</offset><text>Conclusions</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1835</offset><text>Despite fundraising efforts, patients with kidney cancer face persistent financial barriers, incurring both medical and nonmedical cost burdens. This may be compounded by limited or no insurance. Cancer care providers should be aware of financial constraints placed on kidney cancer patients, and consider how these may impact treatment regimens.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>2182</offset><text>This work spotlights online crowdfunding campaigns for patients with kidney cancer. By elucidating patient and campaign characteristics, we are able to better understand the financial needs of this population. </text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>2393</offset><text>INTRODUCTION</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2406</offset><text>Crowdfunding is a relatively novel strategy for patients and their families to source funds during times of added financial stress. Approximately eight million Americans have launched a crowdfunding campaign to cover health‐related expenses. Fifty million Americans report they have contributed to an online, health‐related crowdfunding campaign themselves, which may serve as a lens into national health inequities. The American Society of Clinical Oncology has cited persistent financial barriers for cancer patients, such as the rising cost of cancer medications and increased cost‐sharing burdens. Along with direct costs, indirect costs such as lost employment time, travel costs, and familial responsibilities, impose cumulative “financial toxicity” on cancer patients. This load has been shown to lead to increased medication non‐adherence, reduced frequency of care visits, and increased symptomatology affecting quality of life. Existing crowdfunding literature demonstrates that cancer patients fundraise online for a variety of different reasons, and differentially benefit those from higher socioeconomic backgrounds. While multiple factors may impact cancer patient's crowdfunding; there is a paucity of data evaluating campaigns for urologic cancers.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3683</offset><text>Kidney cancer is associated with particularly high financial burden for many reasons, including the rising cost of novel systemic treatments. The United States (US) has the second highest incidence of kidney cancer around the world and approximately 73,750 new cases are diagnosed annually. Further, Wilms’ tumor accounts for 5% of pediatric cancer cases nationally. Kidney cancer causes significant morbidity, accounting for 79.3 disability‐adjusted life years (DALYs) per 100,000 people, and an estimated 15,000 US patients die each year. It is the sixth most common male cancer in the US, and global rates have risen from 207, 300 incident cases in 1990 to 393, 040 in 2017. Since 2010, health expenditures due to kidney cancer have also been rising. The economic burden of metastatic renal cell carcinoma in the US is estimated to be $107–$556 million US Dollars. With the rising financial burden of kidney cancer care in the US, patients and their families may turn to crowdfunding platforms to cover associated costs. GoFundMe® is a widely‐known crowdfunding platform where one‐third of campaigns are health‐related, and is most commonly referenced in preceding crowdfunding literature. </text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4890</offset><text>There is a dearth of literature describing the characteristics of kidney cancer patients who seek financial support via online, crowdfunding platforms. This study aimed to ascertain the patient, disease, and campaign‐level characteristics of GoFundMe® campaigns for patients with kidney cancer. We aimed to better understand the financial barriers and current needs of this population.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>5279</offset><text>MATERIALS AND METHODS</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>5301</offset><text>Data collection and study sample selection</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5344</offset><text>We performed a cross‐sectional, quantitative, and qualitative analysis of GoFundMe® campaigns for patients with kidney cancer. Data collection has been previously described in multispecialty cancer crowdfunding research. Briefly, Cohen et al. identified the top 20 most prevalent cancers in the US from the National Cancer Institute. Through the GoFundMe® site, they performed 1000 individual searches to identify campaigns for cancer patients in each state (50 states x 20 top cancers = 1000 searches). Any cancer campaign published anywhere in the world since the site's inception in 2010, was included. On October 7, 2018, they used a custom Python code to identify cancer campaigns through web scraping. Web scraping is an automated process that gathers data from websites to allow analysis. Data from a total of 37, 344 cancer campaigns was extracted, and several variables, including cancer type, were recorded by Cohen et al (Figure 1).</text></passage><passage><infon key="file">CAM4-10-4564-g003.jpg</infon><infon key="id">cam43974-fig-0001</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>6296</offset><text>Flowchart of data collection, inclusion and exclusion criteria. *Source: National Cancer Institute</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6395</offset><text>All cancer campaigns were filtered using a custom RStudio code (Version 1.2.1335) based on cancer type in order to isolate patients with a primary kidney malignancy (n = 1043).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>6574</offset><text>Data variables and extraction process</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6612</offset><text>Data were uploaded into Research Electronic Data Capture (REDCap), a secure, online platform for data handling. Basic campaign features were extracted by HST, including campaign ID, creation date, number of months online, and location. In addition, engagement metrics such as number of photos, hearts (“likes”), shares, updates, comments, and trending status (as classified by GoFundMe® algorithm at the time of data extraction), were extracted as well. Variables pertaining to fundraising efforts, including goal funds, amount raised, minimum, and maximum donations, were also identified. “Successful” campaigns were defined as those which met or surpassed their associated fundraising goal as of Oct 7th, 2018.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7334</offset><text>Two study investigators independently reviewed campaign stories (narratives) (HST, AWL) from 50 randomly selected campaigns. Important characteristics were identified through several rounds of iterative discussion, and a list of variables was created for additional extraction. Demographics, including age (adult = ≥18 years old; child = &lt;18 years old), sex, employment, primary wage status, presence of children, insurance status, and history of military service, were extracted from campaign stories. Patient insurance was classed based on self‐reporting (uninsured, underinsured, insured). Where possible, disease characteristics, such as cancer type, stage, status, and treatment regimen, were also collected. We further defined campaign characteristics including authorship, purpose for requested funds, alternative sources of funding, and reference to religion/spirituality.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8225</offset><text>For the qualitative data, a content analysis was performed. Prominent themes pertaining to the patient's main narrative were independently identified from 50 campaigns by HST and AWL, both medical students with interests in urology and kidney cancer. After multiple rounds of discussion, a codebook was created with defined a priori categories (patient's hardship, high moral character, contribution to society, other) for patient's life story primary appeal.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8685</offset><text>Eight study investigators (HST, AWL, BN, NKN, NH, PMT, NR, and AE) were trained via a one‐hour online session on how to perform the quantitative data extraction, and qualitative coding. Afterward, they all independently extracted data from a trial of 15 kidney cancer campaigns and interrater reliability was examined (κ = 0.72). At this stage, repetitive discrepancies in data collection were openly discussed with all investigators and additional training was provided.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>9162</offset><text>Subsequently, each investigator extracted all patient, disease and campaign‐level variables, from a designated number of kidney cancer campaigns. Patient stories were coded into one of the above qualitative categories and exemplar excerpts were collected from each campaign. Due to the volume of campaigns, multiple coders did not code the same campaign. All data extraction and coding was performed in REDCap. </text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>9576</offset><text>During the data extraction process, investigators confirmed the inclusion of campaigns that met the eligibility criteria of a primary kidney malignancy (n = 486). Pediatric kidney malignancies, such as Wilms’ tumor, were included. Excluded campaigns were ​mostly those related to animals or kidney failure secondary to a non‐cancer‐related illness.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>9935</offset><text>Statistical analysis</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>9956</offset><text>Data were exported from the REDCap platform and descriptive statistics were performed using RStudio (Version 1.2.1335). Campaigns were stratified into “all campaigns” and those that were “successful,” as defined above. The denominators for both categories reflect the total number of campaigns, rather than just the campaigns that mentioned the variable. This is important for a sub select of our variables. For example, campaigns which did not mention travel out of state/country for treatment were assumed to not have travelled out of state/country or did not feel it was meaningful enough to include in the campaign narrative. The denominator is therefore reported as the total number of campaigns, regardless. Bivariate analysis was performed to explore differences between patient, disease, and campaign‐level characteristics and campaign success. We used chi‐square or Fisher's exact test to compare categorical variables for differences in proportions. p‐values &lt; 0.05 were statistically significant.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>10980</offset><text>Ethics</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>10987</offset><text>The institutional review board at the University of California, San Francisco deemed this study exempt because all data were publicly available and de‐identified.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>11152</offset><text>RESULTS</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>11160</offset><text>General and fundraising characteristics</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>11200</offset><text>A total of 1043 kidney cancer campaigns were initially filtered from Cohen et al's cohort of GoFundMe® cancer campaigns. Of these, 486 met the above inclusion criteria and were included in the final analysis. Campaigns were posted online for a median of 22 months [Interquartile Range (IQR) = 8.3, 34], shared 154 times [IQR = 65, 350.8] and ‘hearted’ 19 times [IQR = 9, 43]. The median number of comments, updates, and pictures per campaign were 1 [IQR = 0,4], 2 [IQR = 0, 4], and 1 [IQR = 1,1], respectively. Campaigns were located in the West (24.3%, 118/486), Midwest (22%, 107/486), Southeast (20.2%, 98/486), Southwest (16.7%, 81/486), and Northeast (10.3%, 50/486), regions of the US. Elsewhere, campaigns were located in Canada (2.5%, 12/486) and Australia (0.6%, 3/486). A minority of campaigns were trending on the site (3.5%, 17/486).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>12064</offset><text>The median number of donations per campaign was 17 [IQR = 8, 41.8] (Table 1). In general, campaigns were seeking 10,000 US dollars (USD) [IQR = 5000, 20,000], and raised 1450 USD [IQR = 577.5, 4050]. The median minimum and maximum donations were 10 USD [IQR=8.5, 20] and 300 USD [IQR = 100, 500], respectively. Contrastingly, successful campaigns had a median 72 donations per campaign [IQR = 23.8, 120], 5000USD goal amount [IQR = 1000, 10,000] and 6450USD amount raised [IQR=2030, 11, 032].</text></passage><passage><infon key="file">cam43974-tbl-0001.xml</infon><infon key="id">cam43974-tbl-0001</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>12570</offset><text>Fundraising characteristics of online GoFundMe® campaigns for patients with kidney cancer. n = 486</text></passage><passage><infon key="file">cam43974-tbl-0001.xml</infon><infon key="id">cam43974-tbl-0001</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;col style=&quot;border-right:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;col style=&quot;border-right:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;col style=&quot;border-right:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;col style=&quot;border-right:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;thead valign=&quot;top&quot;&gt;&lt;tr style=&quot;border-bottom:solid 1px #000000&quot;&gt;&lt;th align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Fundraising Variable&lt;/th&gt;&lt;th align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;p&gt;All Campaigns (&lt;italic toggle=&quot;yes&quot;&gt;n&lt;/italic&gt; = 486)&lt;/p&gt;
&lt;p&gt;Median [IQR] (USD)&lt;/p&gt;
&lt;/th&gt;&lt;th align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;p&gt;Successful Campaigns (&lt;italic toggle=&quot;yes&quot;&gt;n&lt;/italic&gt; = 40)&lt;/p&gt;
&lt;p&gt;Median [IQR] (USD)&lt;/p&gt;
&lt;/th&gt;&lt;th align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;italic toggle=&quot;yes&quot;&gt;p&lt;/italic&gt;‐value&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Number of donations&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;[&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;17 [8, 41.8]&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;[&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;72 [23.8, 120]&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Goal amount&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;[&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10,000 [5000, 20,000]&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;[&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5000 [1000, 10,000]&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.0002&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Amount raised&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;[&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1450 [577.5, 4050]&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;[&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6450 [2030, 11,032]&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Amount minimum donation&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;[&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10 [8.5, 20]&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;[&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10 [5, 20]&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.0100&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Amount maximum donation&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;[&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;300 [100, 500]&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;[&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;500 [288, 1000]&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.0003&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>12672</offset><text>Fundraising Variable	All Campaigns (n = 486)Median [IQR] (USD)	Successful Campaigns (n = 40)Median [IQR] (USD)	p‐value	 	Number of donations	17 [8, 41.8]	72 [23.8, 120]	&lt;0.0001	 	Goal amount	10,000 [5000, 20,000]	5000 [1000, 10,000]	0.0002	 	Amount raised	1450 [577.5, 4050]	6450 [2030, 11,032]	&lt;0.0001	 	Amount minimum donation	10 [8.5, 20]	10 [5, 20]	0.0100	 	Amount maximum donation	300 [100, 500]	500 [288, 1000]	0.0003	 	</text></passage><passage><infon key="file">cam43974-tbl-0001.xml</infon><infon key="id">cam43974-tbl-0001</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot_title</infon><offset>13105</offset><text>Note</text></passage><passage><infon key="file">cam43974-tbl-0001.xml</infon><infon key="id">cam43974-tbl-0001</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>13110</offset><text>
p−values compare rows with campaign success (unsuccessful vs. successful).</text></passage><passage><infon key="file">cam43974-tbl-0001.xml</infon><infon key="id">cam43974-tbl-0001</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>13188</offset><text>Abbreviations: IQR, interquartile range; USD, US Dollar.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>13245</offset><text>Patient, disease, and campaign‐level characteristics</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>13300</offset><text>The majority of kidney cancer campaigns were for adult male patients (53.3%, 259/486) (Table 2). Seventeen percent of campaigns were for pediatric patients (82/486). Most adult patients had children (61.9%, 249/402). Approximately one third of adult patient campaigns (34.3%, 138/402) mentioned that the patient was employed; however, 43.3% (174/402) reported a job loss or reduction in hours due to illness. Thirty‐seven percent (150/402) of adult patients were primary wage earners within their family. Twenty‐nine percent of campaigns mentioned that the patient had no insurance (10.7%, 52/486) or was under‐covered (18.1%, 88/486). Finally, 10.2% (41/402) of campaigns mentioned that the patient was a veteran or in the military.</text></passage><passage><infon key="file">cam43974-tbl-0002.xml</infon><infon key="id">cam43974-tbl-0002</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>14041</offset><text>Patient, disease, and campaign‐level characteristics of online GoFundMe® campaigns for patients with kidney cancer. n = 486</text></passage><passage><infon key="file">cam43974-tbl-0002.xml</infon><infon key="id">cam43974-tbl-0002</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;col style=&quot;border-right:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;col style=&quot;border-right:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;col style=&quot;border-right:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;col style=&quot;border-right:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;thead valign=&quot;top&quot;&gt;&lt;tr style=&quot;border-bottom:solid 1px #000000&quot;&gt;&lt;th align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Characteristic&lt;/th&gt;&lt;th align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;p&gt;All Campaigns&lt;/p&gt;
&lt;p&gt;
&lt;italic toggle=&quot;yes&quot;&gt;n&lt;/italic&gt; = 486&lt;/p&gt;
&lt;p&gt;
&lt;italic toggle=&quot;yes&quot;&gt;n&lt;/italic&gt; (%)&lt;/p&gt;
&lt;/th&gt;&lt;th align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;p&gt;Successful Campaigns&lt;/p&gt;
&lt;p&gt;
&lt;italic toggle=&quot;yes&quot;&gt;n&lt;/italic&gt; = 40&lt;/p&gt;
&lt;p&gt;
&lt;italic toggle=&quot;yes&quot;&gt;n&lt;/italic&gt; (%)&lt;/p&gt;
&lt;/th&gt;&lt;th align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;italic toggle=&quot;yes&quot;&gt;p&lt;/italic&gt;‐value&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; colspan=&quot;4&quot; rowspan=&quot;1&quot;&gt;Patient&lt;xref rid=&quot;cam43974-note-0003&quot; ref-type=&quot;table-fn&quot;&gt;
&lt;sup&gt;a&lt;/sup&gt;
&lt;/xref&gt;
&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; colspan=&quot;4&quot; rowspan=&quot;1&quot;&gt;Patient age&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Adult&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;402 (82.7)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;30 (75)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.313&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Child&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;82 (16.9)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10 (25)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; colspan=&quot;4&quot; rowspan=&quot;1&quot;&gt;Patient sex&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Male&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;298 (61.3)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;27 (67.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.436&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Female&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;174 (35.8)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;13 (32.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Unknown&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;14 (2.9)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0 (0) 0 (0)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; colspan=&quot;4&quot; rowspan=&quot;1&quot;&gt;Employment status&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Adult, Yes&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;138 (34.3)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;11 (36.7)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.644&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Parent of child, Yes&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;29 (35.4)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5 (50)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.217&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; colspan=&quot;4&quot; rowspan=&quot;1&quot;&gt;Loss of job/reduction of hours due to illness&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Adult, Yes&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;174 (43.3)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;12 (40)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.526&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Parent of child, Yes&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;24 (29.3)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5 (50)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.147&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Patient is primary wage earner&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;150 (37.3)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;14 (46.7)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.447&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Patient has children&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;249 (61.9)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;17 (56.7)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.484&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Patient has children &amp;lt;18y/o&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;77 (19.2)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7 (23.3)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.179&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; colspan=&quot;4&quot; rowspan=&quot;1&quot;&gt;Insurance status&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Covered&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;20 (4.1)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1 (2.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.695&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Under‐covered&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;88 (18.1)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5 (12.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No insurance&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;52 (10.7)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3 (7.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Unknown&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;326 (67.1)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;31 (77.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Patient is in military or a veteran&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;41 (10.2)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2 (6.7)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.330&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; colspan=&quot;4&quot; rowspan=&quot;1&quot;&gt;Disease&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; colspan=&quot;4&quot; rowspan=&quot;1&quot;&gt;Cancer type&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Renal cell carcinoma&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;98 (20.2)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;11 (27.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.219&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Wilms’ tumor&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;41 (8.4)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5 (12.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Other&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;16 (3.3)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2 (5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Unknown&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;331 (68.1)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;22 (55) 22 (55)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; colspan=&quot;4&quot; rowspan=&quot;1&quot;&gt;Cancer stage&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Early (I)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4 (0.8)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0 (0)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.371&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Mid (II or III)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;24 (4.9)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4 (10)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Late (IV+)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;136 (28)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;14 (35)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Unknown&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;317 (65.2)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;22 (55)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; colspan=&quot;4&quot; rowspan=&quot;1&quot;&gt;Cancer status&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Active treatment&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;259 (53.3)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;17 (42.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.097&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Metastasis&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;64 (13.2)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10 (25)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Remission/cure&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;56 (11.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3 (7.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Hospice/end of life&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;23 (4.7)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2 (5) 2 (5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Death&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;36 (7.4)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6 (15)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Unknown&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;47 (9.7)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2 (5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Metastases, yes&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.889&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Bone&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;39 (8)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4 (10)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Lymph Nodes&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;23 (4.7)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2 (5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Brain&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;22 (4.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2 (5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Lung&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;16 (3.3)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1 (2.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Adrenal&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8 (1.6)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1 (2.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Liver&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5 (1)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2 (5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Pancreas&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3 (0.6)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2 (5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Colon&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2 (0.4)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0 (0)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Ovary&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2 (0.4)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0 (0)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Uterus&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1 (0.2)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0 (0)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;None&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;141 (35.2)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10 (25)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Other&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;26 (5.3)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3 (7.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Unknown&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;236 (48.6)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;19 (47.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Travel out of state/country for treatment, yes&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;57 (11.7)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7 (17.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.091&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;History of misdiagnosis or delayed diagnosis, yes&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;24 (4.9)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3 (7.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.209&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Past treatment, yes&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.574&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Surgery&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;222 (45.7)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;15 (37.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Chemotherapy&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;79 (16.3&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7 (17.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Radiation&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;48 (9.9)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3 (7.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Experimental treatment&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10 (2.1)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1 (2.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Immunotherapy&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8 (1.6)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2 (5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Transplant&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3 (0.6)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2 (5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Stem cell treatment&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1 (0.2)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0 (0)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Bone marrow transplant&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0 (0)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0 (0)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;None&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;104 (21.4)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10 (25)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Unknown&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;115 (23.7)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;11 (27.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Future treatment, yes&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.603&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Surgery&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;125 (25.7)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;12 (30)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Chemotherapy&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;90 (18.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6 (15)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Radiation&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;51 (10.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4 (10)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Experimental treatment&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;16 (3.3)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1 (2.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Transplant&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;12 (2.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1 (2.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Immunotherapy&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;9 (1.9)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1 (2.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Stem cell treatment&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2 (0.4)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1 (2.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Bone marrow transplant&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1 (0.2)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0 (0)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;None&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;89 (17.1)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5 (12.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Unknown&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;183 (37.7)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;17 (42.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; colspan=&quot;4&quot; rowspan=&quot;1&quot;&gt;Campaign&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; colspan=&quot;4&quot; rowspan=&quot;1&quot;&gt;Author of GoFundMe® campaign&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Friend&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;140 (28.8)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;13 (32.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.205&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Other family&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;72 (14.8)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4 (10)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Child&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;70 (14.4)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5 (12.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Self&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;64 (13.2)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1 (2.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Spouse&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;26 (5.3)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3 (7.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Parent&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;15 (3.1)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2 (5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; style=&quot;padding-left:10%&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Unknown&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;97 (20)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;12 (30)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Fundraising out with GoFundMe®&lt;xref rid=&quot;cam43974-note-0004&quot; ref-type=&quot;table-fn&quot;&gt;
&lt;sup&gt;b&lt;/sup&gt;
&lt;/xref&gt;
&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;39 (8)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3 (7.5)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.597&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Reference to religion or spirituality&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;206 (42.4)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;(&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;22 (55)&lt;/td&gt;&lt;td align=&quot;char&quot; char=&quot;.&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.092&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>14170</offset><text>Characteristic	All Campaignsn = 486n (%)	Successful Campaignsn = 40n (%)	p‐value	 	Patienta	 	Patient age	 	Adult	402 (82.7)	30 (75)	0.313	 	Child	82 (16.9)	10 (25)		 	Patient sex	 	Male	298 (61.3)	27 (67.5)	0.436	 	Female	174 (35.8)	13 (32.5)		 	Unknown	14 (2.9)	0 (0) 0 (0)		 	Employment status	 	Adult, Yes	138 (34.3)	11 (36.7)	0.644	 	Parent of child, Yes	29 (35.4)	5 (50)	0.217	 	Loss of job/reduction of hours due to illness	 	Adult, Yes	174 (43.3)	12 (40)	0.526	 	Parent of child, Yes	24 (29.3)	5 (50)	0.147	 	Patient is primary wage earner	150 (37.3)	14 (46.7)	0.447	 	Patient has children	249 (61.9)	17 (56.7)	0.484	 	Patient has children &lt;18y/o	77 (19.2)	7 (23.3)	0.179	 	Insurance status	 	Covered	20 (4.1)	1 (2.5)	0.695	 	Under‐covered	88 (18.1)	5 (12.5)		 	No insurance	52 (10.7)	3 (7.5)		 	Unknown	326 (67.1)	31 (77.5)		 	Patient is in military or a veteran	41 (10.2)	2 (6.7)	0.330	 	Disease	 	Cancer type	 	Renal cell carcinoma	98 (20.2)	11 (27.5)	0.219	 	Wilms’ tumor	41 (8.4)	5 (12.5)		 	Other	16 (3.3)	2 (5)		 	Unknown	331 (68.1)	22 (55) 22 (55)		 	Cancer stage	 	Early (I)	4 (0.8)	0 (0)	0.371	 	Mid (II or III)	24 (4.9)	4 (10)		 	Late (IV+)	136 (28)	14 (35)		 	Unknown	317 (65.2)	22 (55)		 	Cancer status	 	Active treatment	259 (53.3)	17 (42.5)	0.097	 	Metastasis	64 (13.2)	10 (25)		 	Remission/cure	56 (11.5)	3 (7.5)		 	Hospice/end of life	23 (4.7)	2 (5) 2 (5)		 	Death	36 (7.4)	6 (15)		 	Unknown	47 (9.7)	2 (5)		 	Metastases, yes			0.889	 	Bone	39 (8)	4 (10)		 	Lymph Nodes	23 (4.7)	2 (5)		 	Brain	22 (4.5)	2 (5)		 	Lung	16 (3.3)	1 (2.5)		 	Adrenal	8 (1.6)	1 (2.5)		 	Liver	5 (1)	2 (5)		 	Pancreas	3 (0.6)	2 (5)		 	Colon	2 (0.4)	0 (0)		 	Ovary	2 (0.4)	0 (0)		 	Uterus	1 (0.2)	0 (0)		 	None	141 (35.2)	10 (25)		 	Other	26 (5.3)	3 (7.5)		 	Unknown	236 (48.6)	19 (47.5)		 	Travel out of state/country for treatment, yes	57 (11.7)	7 (17.5)	0.091	 	History of misdiagnosis or delayed diagnosis, yes	24 (4.9)	3 (7.5)	0.209	 	Past treatment, yes			0.574	 	Surgery	222 (45.7)	15 (37.5)		 	Chemotherapy	79 (16.3	7 (17.5)		 	Radiation	48 (9.9)	3 (7.5)		 	Experimental treatment	10 (2.1)	1 (2.5)		 	Immunotherapy	8 (1.6)	2 (5)		 	Transplant	3 (0.6)	2 (5)		 	Stem cell treatment	1 (0.2)	0 (0)		 	Bone marrow transplant	0 (0)	0 (0)		 	None	104 (21.4)	10 (25)		 	Unknown	115 (23.7)	11 (27.5)		 	Future treatment, yes			0.603	 	Surgery	125 (25.7)	12 (30)		 	Chemotherapy	90 (18.5)	6 (15)		 	Radiation	51 (10.5)	4 (10)		 	Experimental treatment	16 (3.3)	1 (2.5)		 	Transplant	12 (2.5)	1 (2.5)		 	Immunotherapy	9 (1.9)	1 (2.5)		 	Stem cell treatment	2 (0.4)	1 (2.5)		 	Bone marrow transplant	1 (0.2)	0 (0)		 	None	89 (17.1)	5 (12.5)		 	Unknown	183 (37.7)	17 (42.5)		 	Campaign	 	Author of GoFundMe® campaign	 	Friend	140 (28.8)	13 (32.5)	0.205	 	Other family	72 (14.8)	4 (10)		 	Child	70 (14.4)	5 (12.5)		 	Self	64 (13.2)	1 (2.5)		 	Spouse	26 (5.3)	3 (7.5)		 	Parent	15 (3.1)	2 (5)		 	Unknown	97 (20)	12 (30)		 	Fundraising out with GoFundMe®b	39 (8)	3 (7.5)	0.597	 	Reference to religion or spirituality	206 (42.4)	22 (55)	0.092	 	</text></passage><passage><infon key="file">cam43974-tbl-0002.xml</infon><infon key="id">cam43974-tbl-0002</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>17219</offset><text>Proportions were tabulated based on either the number of total patients (n = 486), the number of adult patients (n = 402) or the number of child patients (n = 82), depending on relevant context. For example, for employment status of the parent of the child, the denominator = 82.</text></passage><passage><infon key="file">cam43974-tbl-0002.xml</infon><infon key="id">cam43974-tbl-0002</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>17507</offset><text>Referring to any other form of fundraising for patient's expenses, as mentioned in the campaign story (e.g. community barbeque, gala, etc…). p‐values compare rows with campaign success (unsuccessful vs. successful).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>17727</offset><text>We were largely unable to ascertain which kidney cancer type was present from campaign stories (68.1%, 331/486); however, 20.2% were reported as renal cell carcinoma (RCC) (98/486) (Table 2). Most campaigns reported that patients were in a late stage (28%, 136/486) and undergoing active treatment (53.3%, 259/486). In cases of metastasis, cancer had largely spread to bone (8%, 39/486), lymph nodes (4.7%, 23/486), and brain (4.5%, 22/486). Twelve percent of patients travelled out of state or country for treatment (57/486). Prior to their campaign launch, many patients had already undergone surgery (45.7%, 222/486). Campaigns subsequently mentioned additional surgery (25.7%, 125/486), chemotherapy (18.5%, 90/486), and radiotherapy (10.5%, 51/486) as part of future treatment.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>18511</offset><text>Campaigns were primarily authored by friends of the patient (28.8%, 140/486), other family (14.8%, 72/486), or the patient's child (14.4%, 70/486) (Table 2). The majority of campaigns mentioned that funds contributed towards medical bills (59.7%, 290/486) (Figure 2). Nonmedical bills (27.4%, 133/486), medical travel (23.5%, 114/486), and lost wages (17.7%, 86/486) accounted for much of the remaining funds. Eight percent of campaigns mentioned alternative sources of fundraising out with GoFundMe® (39/486). Approximately 42% of campaigns referenced religion or spirituality (206/486).</text></passage><passage><infon key="file">CAM4-10-4564-g001.jpg</infon><infon key="id">cam43974-fig-0002</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>19102</offset><text>Stated purpose for requested funds among GoFundMe® campaigns for patients with kidney cancer</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>19196</offset><text>Finally, 8.2% of campaigns were deemed “successful” (Table 2). Successful campaigns were mostly for adult (75%, 30/40), male (67.5%, 27/40) patients (Table 2). The majority of adults had children (56.7% 17/30) and near half described themselves as primary wage earners (46.7%, 14/30). Twenty percent of successful campaigns reported no or insufficient insurance (8/40). Patients most commonly sought funds for medical bills (55%, 22/40), nonmedical bills, and medical travel (30%, 12/40) and lodging (20%, 8/40). The majority of successful campaigns referenced religion or spirituality in their campaign story (55%, 22/40).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>19826</offset><text>Qualitative review: patient's life story primary appeal</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>19882</offset><text>Study investigators reviewed campaign stories to evaluate the patient's life story (Table 3). The life story refers to the general sentiment and/or rousing narrative employed by the campaign author to appeal for financial support. Most campaign stories centered around the patient's hardships/ disheartening circumstances (46.3%, 225/486). Anecdotally, for pediatric patients, campaigns often expressed saddened concern for how young the child was. Campaign authors also frequently referenced the patient's high moral character (35.2%, 171/486), praising intrinsic traits such as kindness and compassion and societal archetypes such as devotion to family. Finally, a minority of campaign narratives centered around describing the patient's contribution to society (11.9%, 58/486). This was often conveyed as a patient's particular talent, generosity, or service to community such as military duty. Few campaign primary appeals were captured as “Other.”</text></passage><passage><infon key="file">cam43974-tbl-0003.xml</infon><infon key="id">cam43974-tbl-0003</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>20840</offset><text>Qualitative analysis of patient's life story primary appeal</text></passage><passage><infon key="file">cam43974-tbl-0003.xml</infon><infon key="id">cam43974-tbl-0003</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;col style=&quot;border-right:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;col style=&quot;border-right:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;col style=&quot;border-right:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;col style=&quot;border-right:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;thead valign=&quot;top&quot;&gt;&lt;tr style=&quot;border-bottom:solid 1px #000000&quot;&gt;&lt;th align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Theme&lt;/th&gt;&lt;th align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Definition&lt;/th&gt;&lt;th align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Frequency &lt;italic toggle=&quot;yes&quot;&gt;n&lt;/italic&gt; (%)&lt;/th&gt;&lt;th align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Exemplar excerpts&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Hardship/disheartening circumstances&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Campaign story emphasized the patient's hardships/disheartening circumstances, in an appeal to gather fundraising support (e.g. how young the patient is, many bad things happened back‐to‐back that led to present situation)&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;225 (46.3)&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;p&gt;
&lt;italic toggle=&quot;yes&quot;&gt;“But we found out that when the recession hit back in 2008, revenue slowly started to decline at the restaurant…. Also, during this same period, with housing values declining, like many Americans, their home mortgage was significantly more than the value of their house. We thought that in a few years, they would bounce‐back, which hasn't happened only to be compounded by a series of health issues…”&lt;/italic&gt;
&lt;/p&gt;
&lt;p&gt;
&lt;italic toggle=&quot;yes&quot;&gt;“[Patient name] is only three years old and to have a fighting chance she will need to undergo further treatment…[patient name] also has a beautiful little brother&lt;/italic&gt;, &lt;italic toggle=&quot;yes&quot;&gt;who at the tender age of 18 months wants nothing more than for his big sister to get better so they can play again&lt;/italic&gt;.”&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;High moral character&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Campaign story emphasized positive characteristics and society‐based values that the patient possesses, in an appeal to gather fundraising support (e.g. compassionate, kind, giving person, family man/woman)&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;171 (35.2)&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;p&gt;
&lt;italic toggle=&quot;yes&quot;&gt;“Many know my dad for his sense of humor, his kind smile, and how he is astoundingly and uncannily knowledgeable on just about any random topic you can think of. He is the hardest‐working man I know. He can rebuild a motor, restore a car, cook you the best dinner you've ever had, dazzle you with his storytelling skills, and crack an epic joke (few know he can sing too).”&lt;/italic&gt;
&lt;/p&gt;
&lt;p&gt;
&lt;italic toggle=&quot;yes&quot;&gt;“[Patient name] was the icon of the restaurant, he was the one that made people feel good and enjoy their meal and the atmosphere! He had a zest for life and joy for everyone! Not one customer had a meal there that didn't get enjoy their meal and feel good when they left.”&lt;/italic&gt;
&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Contribution to society&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Campaign story emphasized significant contribution made to community/society by the patient, in an appeal to gather fundraising support (e.g. exquisite talent, veteran/military service, community worker)&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;58 (11.9)&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;p&gt;
&lt;italic toggle=&quot;yes&quot;&gt;“[Patient name] has devoted her entire life to nursing and the care of others. She honorably served her country as a nurse in the US Armed Forces. Being recognized for her dedicated service she obtained the rank Major in the US Army.”&lt;/italic&gt;
&lt;/p&gt;
&lt;p&gt;
&lt;italic toggle=&quot;yes&quot;&gt;“[Patient name] has been a very visible and respected member in the community for decades. Those who know [him], know he is a selfless person who does so much to support and promote all of the great accomplishments by our student‐athletes...”&lt;/italic&gt;
&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Other&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Campaign story emphasized something not captured in the above categories&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;30 (6.2)&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;italic toggle=&quot;yes&quot;&gt;“The purpose of this Go Fund Me account is to raise financial support to fight what is not mine which is kidney cancer (renal cell carcinoma) and provide for the costs of medical bills. Beyond money I covet your prayers and encouragement the most!”&lt;/italic&gt;
&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>20900</offset><text>Theme	Definition	Frequency n (%)	Exemplar excerpts	 	Hardship/disheartening circumstances	Campaign story emphasized the patient's hardships/disheartening circumstances, in an appeal to gather fundraising support (e.g. how young the patient is, many bad things happened back‐to‐back that led to present situation)	225 (46.3)	“But we found out that when the recession hit back in 2008, revenue slowly started to decline at the restaurant…. Also, during this same period, with housing values declining, like many Americans, their home mortgage was significantly more than the value of their house. We thought that in a few years, they would bounce‐back, which hasn't happened only to be compounded by a series of health issues…”“[Patient name] is only three years old and to have a fighting chance she will need to undergo further treatment…[patient name] also has a beautiful little brother, who at the tender age of 18 months wants nothing more than for his big sister to get better so they can play again.”	 	High moral character	Campaign story emphasized positive characteristics and society‐based values that the patient possesses, in an appeal to gather fundraising support (e.g. compassionate, kind, giving person, family man/woman)	171 (35.2)	“Many know my dad for his sense of humor, his kind smile, and how he is astoundingly and uncannily knowledgeable on just about any random topic you can think of. He is the hardest‐working man I know. He can rebuild a motor, restore a car, cook you the best dinner you've ever had, dazzle you with his storytelling skills, and crack an epic joke (few know he can sing too).”“[Patient name] was the icon of the restaurant, he was the one that made people feel good and enjoy their meal and the atmosphere! He had a zest for life and joy for everyone! Not one customer had a meal there that didn't get enjoy their meal and feel good when they left.”	 	Contribution to society	Campaign story emphasized significant contribution made to community/society by the patient, in an appeal to gather fundraising support (e.g. exquisite talent, veteran/military service, community worker)	58 (11.9)	“[Patient name] has devoted her entire life to nursing and the care of others. She honorably served her country as a nurse in the US Armed Forces. Being recognized for her dedicated service she obtained the rank Major in the US Army.”“[Patient name] has been a very visible and respected member in the community for decades. Those who know [him], know he is a selfless person who does so much to support and promote all of the great accomplishments by our student‐athletes...”	 	Other	Campaign story emphasized something not captured in the above categories	30 (6.2)	“The purpose of this Go Fund Me account is to raise financial support to fight what is not mine which is kidney cancer (renal cell carcinoma) and provide for the costs of medical bills. Beyond money I covet your prayers and encouragement the most!”	 	</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>23901</offset><text>DISCUSSION</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>23912</offset><text>This study uniquely described the characteristics of online crowdfunding campaigns for patients with kidney cancer. GoFundMe® kidney cancer campaigns were most frequently utilized for adult, male patients, of whom were in a late disease stage and undergoing active treatment. A high proportion of patients lost their job or reduced their working hours due to illness. In parallel, one quarter reported insufficient or no insurance. Written by friends and family, crowdfunding campaigns for kidney cancer mostly asked for funds to cover medical bills, medical travel, and nonmedical bills such as lost wages. However, per campaign, the median deficit was 8550 USD, meaning patients frequently received less than asked for and only 8% of campaigns were “successful.” There were key descriptive narratives encouraging readers to donate to respective campaigns, including emphasis on patient hardships and high moral character.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>24841</offset><text>Crowdfunding platforms facilitate the opportunity for alignment of patient and donor priorities, ultimately permitting strategic fundraising towards medical expenses. Previous work by Cohen et al. highlighted a significant database of crowdfunding campaigns for patients with prevalent cancer types. When compared with our kidney cancer‐specific analysis, the findings from both studies appeared to support one another. In both, patients sought financial assistance toward medical bills, medical travel, and nonmedical bills. For kidney cancer patients, this may be reflective of literature demonstrating the rising costs of systemic therapies and consequent financial toxicity impacting management decisions. While medical costs remain significant, our results underscored less‐commonly considered indirect cost burdens such as lost wages and lodging as well. Additional research has found that patients also crowdfund in order to cover costs of experimental and “scientifically unsupported” treatments to achieve therapeutic success and pain reduction. However, when compared with more prevalent cancers such as breast, colon and lung, patients with kidney cancer less commonly sought funds for complementary and alternative medicine‐ this was echoed by our results. Instead, patients chiefly called for treatment‐related financial assistance for more widely‐accepted therapies such as nephrectomy, radiotherapy, and chemotherapy. Finally, when compared with Cohen et al.’s multiorgan cancer cohort, it may be notable to mention that a higher proportion of kidney cancer patients reported themselves as the primary wage earner and had subsequent loss of job/reduction of hours due to illness.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>26552</offset><text>In our study, we found that 486 patients with kidney cancer requested financial assistance through GoFundMe® from 2010 to 2018. However, patients with kidney cancer appeared to receive only a small proportion of the total funds sought from their campaign, leaving many with apparent insufficient coverage of medical and nonmedical costs. This may be harmful for patients and their families, alike. Research has shown that financial barriers can result in reduced or delayed access to targeted drug therapies among patients with metastatic RCC. Moreover, despite the advancement of cost‐reduction strategies for children undergoing treatment for Wilms’ tumor, families are often still left indebted. Additional insight from surrounding analyses of GoFundMe® campaigns, suggest that financial cancer burdens are greater for patients living in rural communities than those from urban regions. Rural cancer patients report higher rates of unemployment and no insurance, along with clinical variables such as metastatic cancer rate. In our cohort, the proportion of patients who travelled out of state/country for treatment (11%) may yield insight into the financial influence of proximity to specialized kidney cancer care. Overall, healthcare providers should be vigilant in exploring and addressing financial vulnerabilities for rural patients, during clinical encounters.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>27929</offset><text>Furthermore, within both our cohort and previously‐published multispecialty cancer work, approximately one quarter of campaigns mentioned that patients were uninsured or under covered. In a cohort of high‐income countries, crowdfunding campaigns for routine treatment expenses were more commonly found in the US. Conceptually, crowdfunding may be a proxy for health inequities, pushing users toward reliance on private financing opportunities as health systems do little to support mounting care costs. As crowdfunding methods gain popularity, this may represent a direct reflection of the current healthcare crisis. Comprehensive social health insurance is one such strategy that has been shown to facilitate improved access to cancer care, and benefits are greatest for those most disadvantaged. </text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>28732</offset><text>This study is limited by the depth and breadth of data gathered from online GoFundMe® cancer campaign submissions. Investigators were reliant on self‐reported patient narratives and were unable to confirm the accuracy, and in some cases, the full context of a statement. Denominators are presented as the total numbers of campaigns as with this methodology, it was impossible to ask campaign authors/patients about each specific variable and vary the denominator accordingly. In addition, it is challenging to draw differential conclusions regarding the characteristics and success of GoFundMe® campaigns for kidney cancer patients, in particular, as this study reported no comparator group. Finally, it is largely unclear whether the features of this cohort of GoFundMe® patients were generalizable to those of the general population. However, we believe this is an important step in capturing the habits of this important demographic group and future work exploring crowdfunding for other urologic cancers.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>29746</offset><text>CONCLUSIONS</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>29758</offset><text>Among a cohort of crowdfunding campaigns for patients with kidney cancer, patients faced financial barriers to care, including the loss/reduction of hours at work. As a result, financial assistance was frequently sought for medical bills, medical travel, and nonmedical bills. Despite a variety of patient narratives, campaigns generally did not achieve their target funds, leaving patients with persistent debt. In the absence of successful compensation through crowdfunding, clinicians must continue to advocate for strategies to reduce the financial burden of cancer care for their patients. Collaborative efforts with multispecialty healthcare professionals, including urologists and oncologists, economists, and policymakers should inform future strategies to mitigate financial health inequities for patients with kidney cancer.</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">title_1</infon><offset>30593</offset><text>CONFLICT OF INTEREST</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>30614</offset><text>The authors declares no conflict of interest.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">title</infon><offset>30660</offset><text>REFERENCES</text></passage><passage><infon key="fpage">1093</infon><infon key="lpage">1098</infon><infon key="pub-id_doi">10.1145/2559206.2579406</infon><infon key="section_type">REF</infon><infon key="source">Conf Hum Factors Comput Syst‐Proc</infon><infon key="type">ref</infon><infon key="year">2014</infon><offset>30671</offset><text>Crowdfunding: An emerging field of research</text></passage><passage><infon key="fpage">1623</infon><infon key="issue">16</infon><infon key="lpage">1624</infon><infon key="pub-id_doi">10.1001/jama.2017.3078</infon><infon key="pub-id_pmid">28334321</infon><infon key="section_type">REF</infon><infon key="source">JAMA</infon><infon key="type">ref</infon><infon key="volume">317</infon><infon key="year">2017</infon><offset>30715</offset><text>The rise of crowdfunding for medical care promises and perils</text></passage><passage><infon key="fpage">1</infon><infon key="lpage">6</infon><infon key="section_type">REF</infon><infon key="type">ref</infon><infon key="year">2019</infon><offset>30777</offset><text>NORC AmeriSpeak omnibus survey: millions of Americans donate through crowdfunding sites to help others pay for medical bills</text></passage><passage><infon key="fpage">1</infon><infon key="issue">S1</infon><infon key="lpage">13</infon><infon key="pub-id_doi">10.1186/s12992-019-0519-1</infon><infon key="pub-id_pmid">30606214</infon><infon key="section_type">REF</infon><infon key="source">Global Health</infon><infon key="type">ref</infon><infon key="volume">15</infon><infon key="year">2019</infon><offset>30902</offset><text>Crowdfunding and global health disparities: an exploratory conceptual and empirical analysis</text></passage><passage><infon key="fpage">339</infon><infon key="issue">4</infon><infon key="lpage">383</infon><infon key="pub-id_doi">10.1200/jop.2015.010462</infon><infon key="pub-id_pmid">26979926</infon><infon key="section_type">REF</infon><infon key="source">J Oncol Pract</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">2016</infon><offset>30995</offset><text>2016: A report by the American society of clinical oncology</text></passage><passage><infon key="fpage">381</infon><infon key="issue">4</infon><infon key="lpage">390</infon><infon key="pub-id_doi">10.1634/theoncologist.2012-0279</infon><infon key="pub-id_pmid">23442307</infon><infon key="section_type">REF</infon><infon key="source">Oncologist</infon><infon key="type">ref</infon><infon key="volume">18</infon><infon key="year">2013</infon><offset>31055</offset><text>The financial toxicity of cancer treatment: a pilot study assessing out‐of‐pocket expenses and the insured cancer patient’s experience</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><infon key="year">2019</infon><offset>31196</offset><text>Financial toxicity: a growing burden for cancer patients</text></passage><passage><infon key="fpage">e665</infon><infon key="issue">11</infon><infon key="lpage">e673</infon><infon key="pub-id_doi">10.1200/JOP.18.00120</infon><infon key="section_type">REF</infon><infon key="source">J Oncol Pract</infon><infon key="type">ref</infon><infon key="volume">14</infon><infon key="year">2018</infon><offset>31253</offset><text>Financial toxicity in adults with cancer: Adverse outcomes and noncompliance</text></passage><passage><infon key="fpage">1732</infon><infon key="issue">15</infon><infon key="lpage">1740</infon><infon key="pub-id_doi">10.1200/JCO.2015.63.2232</infon><infon key="pub-id_pmid">26926678</infon><infon key="section_type">REF</infon><infon key="source">J Clin Oncol</infon><infon key="type">ref</infon><infon key="volume">34</infon><infon key="year">2016</infon><offset>31330</offset><text>Association of financial strain with symptom burden and quality of life for patients with lung or colorectal cancer</text></passage><passage><infon key="fpage">383</infon><infon key="issue">4</infon><infon key="lpage">391</infon><infon key="pub-id_doi">10.1056/NEJMsr1601330</infon><infon key="section_type">REF</infon><infon key="source">JAMA Intern Med</infon><infon key="type">ref</infon><infon key="volume">376</infon><infon key="year">2017</infon><offset>31446</offset><text>Use of an online crowdfunding platform for unmet financial obligations in cancer care</text></passage><passage><infon key="elocation-id">e2026946</infon><infon key="issue">12</infon><infon key="pub-id_pmid">33270122</infon><infon key="section_type">REF</infon><infon key="source">JAMA Netw open</infon><infon key="type">ref</infon><infon key="volume">3</infon><infon key="year">2020</infon><offset>31532</offset><text>Association of neighborhood deprivation index with success in cancer care crowdfunding</text></passage><passage><infon key="fpage">e93</infon><infon key="issue">2</infon><infon key="lpage">100</infon><infon key="pub-id_doi">10.1016/j.clgc.2014.08.013</infon><infon key="pub-id_pmid">25450038</infon><infon key="section_type">REF</infon><infon key="source">Clin Genitourin Cancer</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">2015</infon><offset>31619</offset><text>Treatment patterns and costs for metastatic renal cell carcinoma patients with private insurance in the United States</text></passage><passage><infon key="fpage">1495</infon><infon key="issue">12</infon><infon key="lpage">1507</infon><infon key="pub-id_doi">10.1007/s40273-019-00824-2</infon><infon key="pub-id_pmid">31286464</infon><infon key="section_type">REF</infon><infon key="source">Pharmacoeconomics</infon><infon key="type">ref</infon><infon key="volume">37</infon><infon key="year">2019</infon><offset>31737</offset><text>Rising economic burden of renal cell carcinoma among elderly patients in the USA: Part II‐an updated analysis of SEER‐medicare data</text></passage><passage><infon key="fpage">2897</infon><infon key="issue">14</infon><infon key="lpage">2905</infon><infon key="pub-id_doi">10.1002/cncr.31355</infon><infon key="pub-id_pmid">29579342</infon><infon key="section_type">REF</infon><infon key="source">Cancer</infon><infon key="type">ref</infon><infon key="volume">124</infon><infon key="year">2018</infon><offset>31873</offset><text>Cost considerations for systemic therapy for patients with advanced genitourinary malignancies</text></passage><passage><infon key="fpage">1795</infon><infon key="issue">12</infon><infon key="pub-id_doi">10.15419/bmrat.v4i12.386</infon><infon key="section_type">REF</infon><infon key="source">Biomed Res Ther</infon><infon key="type">ref</infon><infon key="volume">4</infon><infon key="year">2017</infon><offset>31968</offset><text>Incidence, mortality and risk factors of kidney cancer in the world</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><infon key="year">2020</infon><offset>32036</offset><text>Cancer Facts &amp; Figures 2020</text></passage><passage><infon key="fpage">1</infon><infon key="issue">1</infon><infon key="lpage">15</infon><infon key="pub-id_doi">10.1186/s40164-020-00181-3</infon><infon key="pub-id_pmid">31908904</infon><infon key="section_type">REF</infon><infon key="source">Exp Hematol Oncol</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">2020</infon><offset>32064</offset><text>The global, regional, and national burden of kidney cancer and attributable risk factor analysis from 1990 to 2017</text></passage><passage><infon key="fpage">1304</infon><infon key="issue">7</infon><infon key="lpage">1312</infon><infon key="pub-id_doi">10.1158/1055-9965.EPI-19-1534</infon><infon key="pub-id_pmid">32522832</infon><infon key="section_type">REF</infon><infon key="source">Cancer Epidemiol Biomarkers Prev</infon><infon key="type">ref</infon><infon key="volume">29</infon><infon key="year">2020</infon><offset>32179</offset><text>Medical care costs associated with cancer survivorship in the United States</text></passage><passage><infon key="fpage">193</infon><infon key="issue">3</infon><infon key="lpage">205</infon><infon key="pub-id_doi">10.1016/j.ctrv.2007.12.001</infon><infon key="pub-id_pmid">18313224</infon><infon key="section_type">REF</infon><infon key="source">Cancer Treat Rev</infon><infon key="type">ref</infon><infon key="volume">34</infon><infon key="year">2008</infon><offset>32255</offset><text>Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review</text></passage><passage><infon key="fpage">1</infon><infon key="lpage">17</infon><infon key="section_type">REF</infon><infon key="type">ref</infon><infon key="year">2020</infon><offset>32357</offset><text>Crowdfunding medical care : a comparison of online medical fundraising in Canada, the United Kingdom, and the United States</text></passage><passage><infon key="fpage">1</infon><infon key="lpage">76</infon><infon key="section_type">REF</infon><infon key="type">ref</infon><infon key="year">2019</infon><offset>32481</offset><text>Facts &amp; Figures</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><infon key="year">2020</infon><offset>32497</offset><text>Web scraping</text></passage><passage><infon key="fpage">377</infon><infon key="issue">2</infon><infon key="lpage">381</infon><infon key="pub-id_doi">10.1016/j.jbi.2008.08.010.Research</infon><infon key="pub-id_pmid">18929686</infon><infon key="section_type">REF</infon><infon key="source">J Biomed Inform</infon><infon key="type">ref</infon><infon key="volume">42</infon><infon key="year">2009</infon><offset>32510</offset><text>Research Electronic Data Capture (REDCap)‐A metadata driven methodology and workflow process for providing translational research informatics support</text></passage><passage><infon key="fpage">1209</infon><infon key="issue">13</infon><infon key="lpage">1220</infon><infon key="pub-id_doi">10.1056/NEJMoa1505425</infon><infon key="pub-id_pmid">27028911</infon><infon key="section_type">REF</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="volume">374</infon><infon key="year">2016</infon><offset>32662</offset><text>Medical crowdfunding for scientifically unsupported or potentially dangerous treatments</text></passage><passage><infon key="fpage">1935</infon><infon key="issue">18</infon><infon key="pub-id_doi">10.1001/jama.2018.3057</infon><infon key="pub-id_pmid">29801003</infon><infon key="section_type">REF</infon><infon key="source">JAMA</infon><infon key="type">ref</infon><infon key="volume">319</infon><infon key="year">2018</infon><offset>32750</offset><text>Crowdfunding for unproven stem cell‐based interventions</text></passage><passage><infon key="fpage">1857</infon><infon key="issue">7</infon><infon key="lpage">1865</infon><infon key="pub-id_doi">10.1007/s00432-020-03191-0</infon><infon key="pub-id_pmid">32219517</infon><infon key="section_type">REF</infon><infon key="source">J Cancer Res Clin Oncol</infon><infon key="type">ref</infon><infon key="volume">146</infon><infon key="year">2020</infon><offset>32808</offset><text>Use of GoFundMe® to crowdfund complementary and alternative medicine treatments for cancer</text></passage><passage><infon key="fpage">158</infon><infon key="issue">4</infon><infon key="lpage">165</infon><infon key="pub-id_doi">10.4021/wjon345w</infon><infon key="pub-id_pmid">29147242</infon><infon key="section_type">REF</infon><infon key="source">World J Oncol</infon><infon key="type">ref</infon><infon key="volume">2</infon><infon key="year">2011</infon><offset>32900</offset><text>Kidney cancer: current progress in treatment</text></passage><passage><infon key="fpage">75</infon><infon key="issue">1</infon><infon key="lpage">86</infon><infon key="pub-id_doi">10.1002/cam4.1262</infon><infon key="pub-id_pmid">29195016</infon><infon key="section_type">REF</infon><infon key="source">Cancer Med</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2018</infon><offset>32945</offset><text>Association of high cost sharing and targeted therapy initiation among elderly Medicare patients with metastatic renal cell carcinoma</text></passage><passage><infon key="fpage">468</infon><infon key="issue">3</infon><infon key="lpage">473</infon><infon key="pub-id_doi">10.1200/JCO.2004.06.058</infon><infon key="pub-id_pmid">14752069</infon><infon key="section_type">REF</infon><infon key="source">J Clin Oncol</infon><infon key="type">ref</infon><infon key="volume">22</infon><infon key="year">2004</infon><offset>33079</offset><text>Effect of duration of treatment on treatment outcome for patients with clear‐cell sarcoma of the kidney: a report from the National Wilms’ Tumor Study Group</text></passage><passage><infon key="elocation-id">e14013</infon><infon key="pub-id_doi">10.1200/JCO.2020.38.15_suppl.e14013</infon><infon key="section_type">REF</infon><infon key="source">J Clin Oncol</infon><infon key="type">ref</infon><infon key="volume">38</infon><infon key="year">2020</infon><offset>33240</offset><text>Rural challenges in a decade of crowdfunding for cancer care</text></passage><passage><infon key="fpage">713</infon><infon key="issue">8</infon><infon key="lpage">720</infon><infon key="pub-id_doi">10.1097/00001888-200608000-00007</infon><infon key="pub-id_pmid">16868424</infon><infon key="section_type">REF</infon><infon key="source">Acad Med</infon><infon key="type">ref</infon><infon key="volume">81</infon><infon key="year">2006</infon><offset>33301</offset><text>The U.S. health care system is in crisis: implications for academic medical centers and their missions</text></passage><passage><infon key="elocation-id">e2027191</infon><infon key="issue">12</infon><infon key="pub-id_doi">10.1001/jamanetworkopen.2020.27191</infon><infon key="pub-id_pmid">33270118</infon><infon key="section_type">REF</infon><infon key="source">JAMA Netw open</infon><infon key="type">ref</infon><infon key="volume">3</infon><infon key="year">2020</infon><offset>33404</offset><text>Crowdfunded cancer care‐a reflection on health care delivery in the US</text></passage><passage><infon key="fpage">638</infon><infon key="issue">10045</infon><infon key="lpage">640</infon><infon key="pub-id_doi">10.1016/S0140-6736(16)30376-2</infon><infon key="pub-id_pmid">27236343</infon><infon key="section_type">REF</infon><infon key="source">Lancet</infon><infon key="type">ref</infon><infon key="volume">388</infon><infon key="year">2016</infon><offset>33477</offset><text>The role of universal health coverage in reducing cancer deaths and disparities</text></passage></document></collection>
